Chronic Myeloproliferative Disorders Withdrawn Phase 2 Trials for Filgrastim (DB00099)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00301912Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic CancerTreatment